Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93.1M
-
Number of holders
-
274
-
Total 13F shares, excl. options
-
75.2M
-
Shares change
-
+1.92M
-
Total reported value, excl. options
-
$3.46B
-
Value change
-
+$104M
-
Put/Call ratio
-
1.38
-
Number of buys
-
139
-
Number of sells
-
-104
-
Price
-
$46.00
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q3 2018
316 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q3 2018.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 274 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.2M shares
of 93.1M outstanding shares and own 80.75% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.5M shares), BAILLIE GIFFORD & CO (9.55M shares), Vanguard Group Inc (8.66M shares), D. E. Shaw & Co., Inc. (3.89M shares), STATE STREET CORP (3.45M shares), DIMENSIONAL FUND ADVISORS LP (2.64M shares), FRONTIER CAPITAL MANAGEMENT CO LLC (2.58M shares), ACADIAN ASSET MANAGEMENT LLC (2.39M shares), Thrivent Financial for Lutherans (2.37M shares), and NORTHERN TRUST CORP (1.66M shares).
This table shows the top 274 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.